Latest News
Web Date: April 16, 2012

Merck Licenses Endocyte Drug

Pharmaceuticals: Late-stage drug and diagnostic could be useful in treating many cancers
Department: Business
News Channels: Biological SCENE
Keywords: pharmaceuticals, oncology, ovarian cancer

Merck & Co. has agreed to pay Endocyte, a West Lafayette, Ind.-based biotech company developing small-molecule drug conjugates, up to $1 billion for access to the cancer agent vintafolide and a companion diagnostic.

Under the pact, Endocyte gets $120 million up front and up to $880 million in milestone payments if the drug gains approval to treat multiple types of cancer. Endocyte will be responsible for paying for most . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society